糖尿病：长效胰岛素类似物——益处是否值得成本？ - Suppr

Suppr

超能文献

Diabetes: long-acting insulin analogues--are benefits worth the cost?

作者信息

Nathan David M

出版信息

Nat Rev Endocrinol. 2012 Dec;8(12):699-700. doi: 10.1038/nrendo.2012.208. Epub 2012 Nov 13.

DOI:10.1038/nrendo.2012.208

PMID:23147577

Abstract

摘要

相似文献

Diabetes: long-acting insulin analogues--are benefits worth the cost?

Nat Rev Endocrinol. 2012 Dec;8(12):699-700. doi: 10.1038/nrendo.2012.208. Epub 2012 Nov 13.

Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.

Diabetes. 2013 Feb;62(2):490-7. doi: 10.2337/db12-0598. Epub 2012 Oct 9.

Setmelanotide (Imcivree) for rare genetic forms of obesity.

Med Lett Drugs Ther. 2021 Jul 26;63(1629):e3-e4.

Novel α-MSH analog causes weight loss in obese rats and minipigs and improves insulin sensitivity.

J Endocrinol. 2014 Jan 8;220(2):97-107. doi: 10.1530/JOE-13-0284. Print 2014 Feb.

Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.

J Med Chem. 2006 Jul 13;49(14):4035-43. doi: 10.1021/jm058241a.

The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.

Mol Metab. 2021 Jun;48:101206. doi: 10.1016/j.molmet.2021.101206. Epub 2021 Mar 6.

Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.

Diabetes Obes Metab. 2018 Feb;20(2):319-327. doi: 10.1111/dom.13068. Epub 2017 Aug 22.

Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity.

Arq Bras Cardiol. 2007 Dec;89(6):409-14. doi: 10.1590/s0066-782x2007001800010.

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.

Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30.

Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues.

J Med Chem. 2012 Mar 8;55(5):1969-77. doi: 10.1021/jm201489a. Epub 2012 Feb 24.

引用本文的文献

A programmable synthetic lineage-control network that differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like cells.

Nat Commun. 2016 Apr 11;7:11247. doi: 10.1038/ncomms11247.

本文引用的文献

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.

Diabetes Care. 2012 Nov;35(11):2174-81. doi: 10.2337/dc11-2503. Epub 2012 Aug 28.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9.

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

N Engl J Med. 2011 Dec 22;365(25):2366-76. doi: 10.1056/NEJMoa1111732. Epub 2011 Nov 12.

Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons.

Diabetes Res Clin Pract. 2011 Dec;94(3):333-9. doi: 10.1016/j.diabres.2011.09.001. Epub 2011 Oct 11.

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Diabetes Care. 2011 Mar;34(3):661-5. doi: 10.2337/dc10-1925. Epub 2011 Jan 26.

Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.

Diabetes Obes Metab. 2009 Apr;11(4):372-8. doi: 10.1111/j.1463-1326.2008.00976.x.

Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

Diabetes Care. 2009 Jan;32(1):32-7. doi: 10.2337/dc08-0332. Epub 2008 Oct 22.

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

N Engl J Med. 2005 Dec 22;353(25):2643-53. doi: 10.1056/NEJMoa052187.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401.

Insulin availability among International Diabetes Federation member associations. Report of the Task Force on Insulin Distribution.

Diabetes Care. 1994 Mar;17(3):220-3. doi: 10.2337/diacare.17.3.220.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验